NEBIDO 1000MG 4ML SOLUTION FOR INJECTION

admin2

NEBIDO 1000MG 4ML SOLUTION FOR INJECTION

Experimental data in rats have shown increased incidences of prostatecancer after treatment with testosterone. Cases of benign and malignant liver tumours have been reported in users of hormonal substances such as androgen compounds. If severe upper abdominal complaints, liver enlargement or signs of intra-abdominal haemorrhage occur in men using Nebido, a liver tumour should be included in the differential-diagnostic considerations.

Like all medicines, this medicine can cause side effects, although not everybody gets them. This medicine contains 2000 mg benzyl benzoate in each 4 ml ampoule/vial which is equivalent to 500 mg/ml. Nebido is not for use in women and must not be used in pregnant or breast-feeding women. There is no need for your doctor to adjust the dose if you are over 65 (see “Medical examination/follow-up”). There is a pre-scored mark beneath the coloured point on the ampoule eliminating the need to file the neck.

SUMMARY OF PRODUCT CHARACTERISTICS

Synonyms or related conditions are not listed, but should be taken into account as well. Testosterone replacement therapy may reversibly reduce spermatogenesis (see sections 4.8 and 5.3). This medicine contains 2000 mg Benzyl benzoate in each 4 ml ampoule/vial which is equivalent to 500 mg/ml.

There is no data available on the use of Nebido in males under 18 years of age. Nebido has no observed effect on your ability to drive or use machines. Individuals who have abused testosterone may become dependent and may experience withdrawal symptoms when the dosage changes significantly or is stopped immediately. Always take this medicine exactly as your doctor or pharmacist has told you. There is no data available on the use of Nebido in males under 18 years of age. Toxicological studies have not revealed other effects than those which can be explained based on the hormone profile of Nebido.

Medicines

Nebido is not indicated for use in women and must not be used in pregnant or breast-feeding women, see section 4.3. Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction. Medicines should not be disposed of via wastewater or household waste. This medicine contains 2000 mg benzyl benzoate in each 4 ml ampoule/vial which is equivalent to 500 mg/ml.

  • Following intravenous infusion of testosterone to elderly men, the elimination half-life of testosterone was approximately one hour and an apparent volume of distribution of about 1.0 l/kg was determined.
  • The injection interval should be within the recommended range of 10 to 14 weeks.
  • However, it should be taken into account that physiologically testosterone serum levels are lower with increasing age.
  • This medicine contains 2000 mg benzyl benzoate in each 4 ml ampoule/vial which is equivalent to 500 mg/ml.

The contents of an ampoule / vial are to be injected intramuscularly immediately after opening. (For the ampoule see section 6.6 for instructions on opening the ampoule safely). Your doctor will inject Testosterone Undecanoate (1 vial) very https://doggiespub.com/ghrp-6-10-mg-peptide-sciences-how-to-buy/ slowly into a muscle.

Nebido is not indicated for use in children and adolescents and it has not been clinically evaluated in males under 18 years of age (see section 4.4). The most appropriate MedDRA term to describe a certain adverse reaction is listed. Synonyms or related conditions are not listed, but should be taken into account as well. •    hypersensitivity to the active substance or to any of the excipients. Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences. If your medicine shows signs of deterioration or discolouration seek the advice of your pharmacist who will tell you what to do.

Like all medicines, this medicine can cause side effects, although not everybody gets them. Nebido is not for use in women and must not be used in pregnant or breast-feeding women. There is no need for your doctor to adjust the dose if you are over 65 (see “Medical examination/Follow-up ”).

No formal studies have been performed in patients with hepatic impairment. The use of Nebido is contraindicated in men with past or present liver tumours (see section 4.3). Testosterone replacement therapy for male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests (see section 4.4). Special care will be taken to avoid injection into a blood vessel (see “Administrati­on ”). Male hormones may increase the growth of prostate cancer and enlarged prostate glands (benign prostatic hypertrophy).